-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QT3mfnzqsMi4zEXyXO4lnieCIZuyMoIfvORFyNp1TWGA9GjY9tS3p4tPxrI+IwHu
 yrU0e2wYw4U0UnJTpg/dlQ==

<SEC-DOCUMENT>0000950131-03-001319.txt : 20030313
<SEC-HEADER>0000950131-03-001319.hdr.sgml : 20030313
<ACCEPTANCE-DATETIME>20030313104148
ACCESSION NUMBER:		0000950131-03-001319
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20030313
ITEM INFORMATION:		Financial statements and exhibits
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20030313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BAXTER INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000010456
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				360781620
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-04448
		FILM NUMBER:		03601770

	BUSINESS ADDRESS:	
		STREET 1:		ONE BAXTER PKWY
		STREET 2:		DF2-2W
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015
		BUSINESS PHONE:		8479482000

	MAIL ADDRESS:	
		STREET 1:		ONE BAXTER PARKWAY
		STREET 2:		DF2-2W
		CITY:			DEERFIELD
		STATE:			IL
		ZIP:			60015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BAXTER LABORATORIES INC
		DATE OF NAME CHANGE:	19760608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BAXTER TRAVENOL LABORATORIES INC
		DATE OF NAME CHANGE:	19880522
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.txt
<DESCRIPTION>FORM 8-K
<TEXT>
<PAGE>

            ________________________________________________________

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                            _______________________

                                    FORM 8-K

                                 Current Report

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                                 March 13, 2003
                                 --------------
                                 Date of Report


                            BAXTER INTERNATIONAL INC.
                            -------------------------
             (Exact name of registrant as specified in its charter)

                                    Delaware
                                    --------
                 (State or other jurisdiction of incorporation)

         1-4448                                           36-0781620
- ---------------------------                    ---------------------------------
(Commission file number)                       (IRS Employer Identification No.)


One Baxter Parkway, Deerfield, Illinois                       60015
- ---------------------------------------                       ------
(Address of principal executive offices)                   (Zip Code)

       Registrant's telephone number, including area code: (847) 948-2000
            ________________________________________________________


<PAGE>

Item 7.   Exhibits.

99        Press Release dated March 13, 2003.

Item 9.   Regulation FD Disclosure

     On March 13, 2003, Baxter International Inc. issued the attached press
     release announcing revised sales growth and earnings per share expectations
     for the first quarter and full year 2003. The press release is filed as
     Exhibit 99.

<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                            BAXTER INTERNATIONAL INC.
                                            -------------------------
                                                  (Registrant)



                                            By: /S/ Jan Stern Reed
                                                ------------------------------
                                                Jan Stern Reed
                                                Corporate Secretary

Date: March 13, 2003


<PAGE>

                                  Exhibit Index

Exhibit No.    Description

99             Press Release dated March 13, 2003.






</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>dex99.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>
<PAGE>


                                                                      Exhibit 99

[LOGO APPEARS HERE]

FOR IMMEDIATE RELEASE
- --------------------

Media contacts:        Deborah Spak, (847) 948-2349
                       Sally Benjamin Young, (847) 948-2304

Investor contacts:     Neville Jeharajah, (847) 948-2875
                       Mary Kay Ladone, (847) 948-3371

            BAXTER REVISES SALES GROWTH AND EARNINGS EXPECTATIONS FOR
                        FIRST QUARTER AND FULL YEAR 2003

         Financial Outlook, Upcoming Product Launches and Collaborations
                Will be Highlighted At Investor Conference Today

     DEERFIELD, Ill., March 13, 2003 - Baxter International Inc. (NYSE:BAX)
today announced it has revised its sales growth and earnings per share
expectations for the first quarter and full year 2003.

     Based on increased competition and pricing pressures in the plasma-protein
market, reductions in inventory by some providers resulting from increased
confidence in the availability of recombinant factor VIII products, and
devaluing currencies in Latin America and Turkey, Baxter has revised its
expectations for the first quarter and the full year 2003.

     Specifically, Baxter now expects to achieve sales growth in the 5 to 7
percent range and earnings per diluted share of $0.36 to $0.38 in the first
quarter of 2003. For full-year 2003, Baxter expects to achieve sales growth from
continuing operations in the 8 to 12 percent range, earnings per share in the
$2.10 to $2.20 range, and to generate cash flow from operations of $1.3 billion
to $1.5 billion before capital expenditures.

                                    - more -

<PAGE>

Baxter Investor Conference - Page 2
- -----------------------------------

     "Increased market competition in the plasma protein business and economic
instability in some overseas markets are impacting our business," said Harry M.
Jansen Kraemer, Jr., chairman and chief executive officer. "Despite our lowered
expectations, we anticipate continuing growth across all our businesses in 2003
and beyond. As we will outline in our conference today, we are introducing many
new products and developing innovative technologies that provide considerable
benefits for health-care providers and patients worldwide."

     Executives from the company will elaborate on Baxter's financial outlook at
its investor conference for investors to be conducted today in Chicago and
webcast live via www.baxter.com.

     During its conference, the company will summarize its comprehensive product
portfolio and unique mix of technology platforms that are expected to drive
long-term, sustainable competitive advantage. The company also will announce
several collaborations, product approvals and contracts, all of which leverage
Baxter's extensive manufacturing and product development expertise to
commercialize innovative technologies, introduce products into new markets, and
tap its specialty sales channels around the globe.

     "Our unique combination of expertise in medical devices, pharmaceuticals
and biotechnology creates a tremendous competitive advantage for Baxter, and
makes us a valued partner to other companies," Kraemer added. "Building upon our
pioneering heritage and proven track record of success, we will sustain growth
by commercializing

                                    - more -

<PAGE>

Baxter Investor Conference - Page 3
- -----------------------------------

innovative technologies, launching new products and expanding into new markets,
and leveraging the strong customer relationships and sales channels we have
established throughout the world."

Launching New Products and Expanding into New Markets

     Several new products are expected to contribute to Baxter's growth in 2003
and beyond. The most significant Baxter product approval anticipated in 2003 is
ADVATE, the first Factor VIII recombinant therapy to be clinically developed and
prepared without the addition of any human- or animal-derived raw materials.
ADVATE is currently under review in the United States, Europe and Canada, and is
expected to launch in the United States in 2003. ADVATE leverages the company's
innovative protein-development and manufacturing capability and further enhances
the most comprehensive portfolio of anti-hemophilia products from one company.

Commercializing Innovative Technologies

     Baxter executives also will showcase the company's range of proprietary and
specialized drug formulation and delivery platforms that it offers to
traditional pharmaceutical as well as biotechnology companies, including
lyophilization, ready-to-use pre-filled syringes, vials, cartridges used in pen-
and auto-injectors, and intravenous bags. Baxter's unique drug delivery
technologies, including formulation technologies for insoluble drugs and
technologies for sustained release, coupled with its long-standing relationships
with pharmaceutical companies have yielded contracts with the 12 largest global
pharmaceutical companies and eight of the top ten biopharmaceutical companies.

                                    - more -

<PAGE>

Baxter Investor Conference - Page 4
- -----------------------------------

Based on Baxter's strengths in service and technology, 11 new compounds were
launched in 2002 and launches for up to an additional 20 compounds are
anticipated in the next two years.

     Baxter also has signed two agreements that capitalize on its strengths in
commercializing innovative technologies. In an exclusive license with Cytokine
PharmaSciences, Inc., Baxter obtained the rights to Cytokine's anti-macrophage
migration inhibitory factor (MIF) antibody technology, which shows potential in
a wide spectrum of diseases, including asthma, severe infections and certain
cancers. And, tapping Baxter's cell-culture and manufacturing expertise, the
company signed a non-exclusive collaboration with Fremont, Calif.-based Protein
Design Labs, Inc. to humanize, develop and manufacture therapeutic monoclonal
antibodies on behalf of other companies.

Leveraging Strong Customer Relationships

     With its global infrastructure and strong customer relationships, Baxter is
well-positioned to increase access to needed therapies. To that end, Baxter has
signed an exclusive agreement with Cangene Corporation to market WinRho SDF in
Europe, excluding Portugal, for the treatment of a critical blood clotting
disorder called Immune Thrombocytopenic Purpura (ITP).

About Baxter

     Baxter International Inc., through its subsidiaries, assists health-care
professionals and their patients with treatment of complex medical conditions,
including cancer, hemophilia, immune disorders, kidney disease and trauma. The
company applies its

                                    - more -

<PAGE>

Baxter Investor Conference - Page 5
- -----------------------------------

expertise in medical devices, pharmaceuticals and biotechnology to make a
meaningful difference in patients' lives. Please visit the company's website at
www.baxter.com for more information about Baxter and to access a webcast of
today's investor conference.

     This news release contains forward-looking statements that involve risks
and uncertainties, including technological advances in the medical field,
product demand and market acceptance, the effect of economic conditions, actions
of regulatory bodies, the impact of competitive products and pricing, foreign
currency exchange rates and other risks detailed in the company's filings with
the Securities and Exchange Commission. These forward-looking statements are
based on estimates and assumptions made by management of the company and are
believed to be reasonable, though are inherently uncertain and difficult to
predict. Actual results or experience could differ materially from the
forward-looking statements.

(Baxter and ADVATE are trademarks of Baxter International Inc. and its
affiliates. WinRho SDF is a trademark of Cangene Corporation.)

                                      # # #



</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
